Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Aplidin
2. Aplidine
3. Dehydrodidemnin B
1. Aplidine
2. Aplidin
3. 137219-37-5
4. Dehydrodidemnin B
5. Y76id234hw
6. Chebi:90205
7. Plitidepsin (inn)
8. Plitidepsin [inn]
9. (2s)-n-[(2r)-1-[[(3s,6s,8s,12s,13r,16s,17r,20s,23s)-13-[(2s)-butan-2-yl]-12-hydroxy-20-[(4-methoxyphenyl)methyl]-6,17,21-trimethyl-3-(2-methylpropyl)-2,5,7,10,15,19,22-heptaoxo-8-propan-2-yl-9,18-dioxa-1,4,14,21-tetrazabicyclo[21.3.0]hexacosan-16-yl]amino]-4-methyl-1-oxopentan-2-yl]-n-methyl-1-(2-oxopropanoyl)pyrrolidine-2-carboxamide
10. Plitidepsin [inn:ban]
11. Plitidepsina
12. Plitidepsine
13. Plitidepsium
14. Unii-y76id234hw
15. Aplidine [mi]
16. Plitidepsin [mi]
17. Plitidepsin [mart.]
18. Plitidepsin [who-dd]
19. Didemnin A, N-(1-(1,2-dioxopropyl)-l-prolyl)-
20. Chembl451930
21. 2-9-didemnin B, 2-(1-(1,2-dioxopropyl)-l-proline)-
22. Schembl13413427
23. Gtpl11396
24. (s)-n-((r)-1-(((3s,6r,7s,10r,11s,15s,17s,20s,25as)-10-((s)-sec-butyl)-11-hydroxy-20-isobutyl-15-isopropyl-3-(4-methoxybenzyl)-2,6,17-trimethyl-1,4,8,13,16,18,21-heptaoxodocosahydro-15h-pyrrolo[2,1-f][1,15]dioxa[4,7,10,20]tetraazacyclotricosin-7-yl)amino)-4-methyl-1-oxopentan-2-yl)-n-methyl-1-(2-oxopropanoyl)pyrrolidine-2-carboxamide
25. At23636
26. Db04977
27. Hy-16050
28. Cs-0006129
29. D11032
30. Q4779975
31. Y-100032
32. (2s)-n-[(2r)-1-[[(3s,6s,8s,12s,13r,16s,17r,20s,23s)-13-[(2s)-butan-2-yl]-12-hydroxy-20-[(4-methoxyphenyl) Methyl]-6,17,21-trimethyl-3-(2-methylpropyl)-2,5,7,10,15,19,22-heptaoxo-8-propan-2-yl-9,18-dioxa-1,4,14,21-tetrazabicyclo[21.3.0]hexacosan-16-yl]amino]-4-methyl-1-oxopentan-2-yl]-n-methyl-1-(2-oxopropanoyl)pyrrolidine-2-carboxamide
33. 1-(2-oxopropanoyl)-l-prolyl-n-[(3s,6r,7s,10r,11s,15s,17s,20s,25as)-10-[(2s)-butan-2-yl]-11-hydroxy-3-(4-methoxybenzyl)-2,6,17-trimethyl-20-(2-methylpropyl)-1,4,8,13,16,18,21-heptaoxo-15-(propan-2-yl)docosahydro-15h-pyrrolo[2,1-f][1,15,4,7,10,20]dioxatetraazacyclotricosin-7-yl]-n(2)-methyl-d-leucinamide
34. 3,6-anhydro(n-((2s,4s)-4-((3s,4r,5s)-3-hydroxy-4-((n-(2-oxopropanoyl)-l-prolyl-n-methyl-d-leucyl-l-threonyl)amino)-5-methylheptanoyloxy)-2,5-dimethyl-3-oxohexanoyl)-l-leucyl-l-prolyl-n,o-dimethyl-l-tyrosine)
35. L-tyrosine, 1-(1,2-dioxopropyl)-l-prolyl-n-methyl-d-leucyl-l-threonyl-(3s,4r,5s)-4-amino-3-hydroxy-5-methylheptanoyl-(2s,4s)-4-hydroxy-2,5-dimethyl-3-oxohexanoyl-l-leucyl-l-prolyl-n,o-dimethyl-, (8-3)-lactone
Molecular Weight | 1110.3 g/mol |
---|---|
Molecular Formula | C57H87N7O15 |
XLogP3 | 5.7 |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 15 |
Rotatable Bond Count | 15 |
Exact Mass | 1109.62601509 g/mol |
Monoisotopic Mass | 1109.62601509 g/mol |
Topological Polar Surface Area | 285 Ų |
Heavy Atom Count | 79 |
Formal Charge | 0 |
Complexity | 2200 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 12 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Intended for the treatment of various forms of cancer.
L - Antineoplastic and immunomodulating agents
L01 - Antineoplastic agents
L01X - Other antineoplastic agents
L01XX - Other antineoplastic agents
L01XX57 - Plitidepsin
Hepatic
Aplidine inhibits the growth and induces apoptosis in MOLT-4 cells through the indirect inhibition of VEGF secretion which blocks the VEGF/VEGFR-1 autocrine loop necessary for the growth of these cells.
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?